Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients

Neurology

Volumn 64, Issue 2, 2005, Pages 282-289

  Chao, L L ^a,b,c,h   Schuff, N ^a,b   Kramer, J H ^a,b   Du, A T ^a,b   Capizzano, A A ^d   O'Neill, J ^e   Wolkowitz, O M ^c   Jagust, W J ^f   Chui, H C ^g   Miller, B L ^b   Yaffe, K ^b,c   Weiner, M W ^a,b,c  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N ACETYLASPARTIC ACID;

AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN ATROPHY; BRAIN METABOLISM; BRAIN SIZE; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; GRAY MATTER; HIPPOCAMPUS; HUMAN; MALE; MEMORY; NEOCORTEX; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; PRIORITY JOURNAL; RISK ASSESSMENT; TEMPORAL LOBE; VERBAL MEMORY;

EID: 19944431158     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000149638.45635.FF     Document Type: Article

References (35)

1. Laukka EJ, Jones S, Small BJ, Fratiglioni L, Backman L. Similar patterns of cognitive deficits in the preclinical phases of vascular dementia and Alzheimer's disease. J Int Neuropsychol Soc 2004;10:382-391.
2. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001;56:592-598.
3. Crook TH, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon S. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change: report of a National Institute of Mental Health Work Group. Dev Neuropsychol 1986;2:261-276.
4. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
5. 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer's disease. J Am Geriatr Soc 1996;44:133-138.
6. Kantarci K, Reynolds G, Petersen RC, et al. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. Am J Neuroradiol 2003;24:843-849.
7. 1H MRS study. Neurology 2000;55:210-217.
8. Chantal S, Braun CM, Bouchard RW, Labelle M, YB. Similar (1)H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 2004;1003:26-35.
9. Schuff N, Capizzano AA, Du AT, et al. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 2002;58:928-935.
10. Jack CR, Jr., Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000;55:484-489.
11. Jack CR, Jr., Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397-1403.
12. Petersen RC, Jack CR, Jr., Xu YC, et al. Memory and MRI-based hippocampal volumes in aging and AD. Neurology 2000;54:581-587.
13. Jessen F, Block W, Traber F, et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 2001;57:930-932.
14. Chantal S, Labelle M, Bouchard RW, Braun CM, Boulanger Y. Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease. Arch Neurol 2002;59:955-962.
15. Tierney MC, Fisher RH, Lewis AJ, et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases. Neurology 1988;38:359-364.
16. McKhann G, Drachman D, Folstein M, Katzman K, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
17. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992;42:473-480.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
19. Williams JM. Memory Assessment Scales. Odessa, FL: 1991.
20. 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2001;45:899-907.
21. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann NY Acad Sci 1987;(508):333-348.
22. Schuff N, Amend D, Ezekiel F, et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 1997;49:1513-1521.
23. Du AT, Schuff N, Amend D, et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;71:441-447.
24. Tanabe JL, Amend D, Schuff N, et al. Tissue segmentation of the brain in Alzheimer disease. Am J Neuroradiol 1997;18:115-123.
25. Soher BJ, Young K, Govindaraju V, Maudsley AA. Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med 1998;40:822-831.
26. Convit A, de Leon MJ, Tarshish C, et al. Hippocampal volume losses in minimally impaired elderly. Lancet 1995;345:266.
27. Pennanen C, Kivipelto M, Tuomainen S, et al. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging 2004;25:303-310.
28. Catani M, Cherubini A, Howard R, et al. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 2001;12:2315-2317.
29. Schuff N, Capizzano AA, Du AT, et al. Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia. Neurology 2003;61:358-364.
30. Gonen O, Gruber S, Li BS, Mlynarik V, Moser E. Multivoxel 3D proton spectroscopy in the brain at 1.5 versus 3.0 T: signal-to-noise ratio and resolution comparison. Am J Neuroradiol 2001;22:1727-1731.
31. Dujn JH, Matson GB, Maudsley AM, Hugg HW, Weiner MW. Proton magnetic resonance spectroscopy in human cerebral infarction. Radiology 1992;183:711-718.
32. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990;14:154-159.
33. Jack CR, Jr., Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004;62:591-600.
34. Braak H, Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 1996;165:3-12.
35. Squire LR. Memory and the hippocampus: a synthesis from findings with rats, monkeys, and humans. Psychol Rev 1992;99:195-231.